Novogen Limited (NASDAQ:KZIA) Receives Average Recommendation of “Moderate Buy” from Analysts

Novogen Limited (NASDAQ:KZIA) has been given a consensus recommendation of “Moderate Buy” by the five brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $23.75.

KZIA has been the subject of several research analyst reports. Wall Street Zen lowered shares of Novogen from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Lake Street Capital started coverage on shares of Novogen in a report on Thursday. They issued a “buy” rating and a $32.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a research report on Tuesday, April 21st. Finally, Laidlaw started coverage on shares of Novogen in a report on Wednesday, April 15th. They issued a “buy” rating and a $25.00 target price for the company.

Novogen Price Performance

NASDAQ:KZIA traded up $0.48 on Thursday, reaching $11.98. The company’s stock had a trading volume of 51,300 shares, compared to its average volume of 217,795. Novogen has a 12-month low of $4.86 and a 12-month high of $17.40. The stock has a 50 day moving average price of $11.49 and a 200 day moving average price of $9.23.

Novogen (NASDAQ:KZIA) last released its quarterly earnings results on Saturday, February 14th. The company reported ($1.34) earnings per share for the quarter. The firm had revenue of $4.89 million during the quarter. Equities analysts expect that Novogen will post -0.01 EPS for the current year.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.